DIADIA0.48%
SPYSPY0.10%
QQQQQQ1.12%
Trending
Top trending tickerSHIBSHIB26.38%
DOGEDOGE3.94%
PEPEPEPE5.78%
OCULOCUL1.33%
PIPI0.27%
CRSRCRSR2.28%
VELOVELO4.35%
TAOTAO0.25%
COHRCOHR9.84%
WBDWBD0.69%
Top trending tickerSHIBSHIB26.38%
DOGEDOGE3.94%
PEPEPEPE5.78%
OCULOCUL1.33%
PIPI0.27%
CRSRCRSR2.28%
VELOVELO4.35%
TAOTAO0.25%
COHRCOHR9.84%
WBDWBD0.69%

Feed

News

Sentiment

Fundamentals

Info

homeSymbolCTORnews
Exchange: NASDAQ·Updated 06:57 PM EDT
CTOR logo

CTORCitius Oncology Inc.

$0.5622
$0.016
(2.77%)
Today
Closed $0.5622
$0.0048
(0.85%)
After Hours
Mkt Cap$52.27M
Vol55,823.00
News
all
press releases
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption PR Newswire CRANFORD, N.J., July 21, 2026 Expanded...
PR Newswire
More News
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin...
PR Newswire
Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting PR...
PR Newswire
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides...
PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and...
PR Newswire
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR Commercialization PR Newswire CRANFORD, N.J., May 5, 2026 Avenue Capital Group to...
PR Newswire
Citius Oncology Ships First International Order of LYMPHIR to Europe
Citius Oncology Ships First International Order of LYMPHIR to Europe Citius Oncology Ships First International Order of LYMPHIR to Europe PR Newswire CRANFORD, N.J., April 29, 2026 Order fulfilment expands international patient access to LYMPHIR following initial U.S. launchDistribution by regional...
PR Newswire
Citius Oncology (NASDAQ:CTOR) Trading 9% Higher - What's Next?
Citius Oncology (NASDAQ:CTOR) Trading Up 9% - Time to Buy...
MarketBeat
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting...
PR Newswire
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts PR Newswire CRANFORD...
PR Newswire
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.